Interim Results for the six months ended June 30, 2024

LARGE PHARMA STRATEGY IMPLEMENTED SUCCESSFULLY

Three Large Pharma contracts secured each with substantial revenue potential. Strategic decision post period end to focus resources on pharma services.

GUILDFORD, SURREY / ACCESSWIRE / September 26, 2024 / ANGLE plc

ANGLE plc (“ANGLE” or “the Company”) ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, today announces unaudited interim results for the six months ended 30 June 2024.

Financial Highlights

Revenues for the half-year of £1.0 million (H1 2023: £1.2 million) – sold order book of up to £1.9 million at period end. Business re-shaped and streamlined with major focus on large pharma – cost savings of c.

ANGLE plc has successfully implemented its large pharma strategy by securing three contracts with substantial revenue potential. This strategic decision was made to focus resources on pharma services post the period end, showcasing the Company’s commitment to growth and sustainability.

Despite a slight decrease in revenues compared to the same period last year, ANGLE plc has managed to maintain a solid order book of up to £1.9 million, indicating a strong pipeline of future business. The re-shaping and streamlining of the business, with a major focus on large pharma, have also resulted in significant cost savings.

How will this affect me?

As a stakeholder or potential investor in ANGLE plc, the successful implementation of the large pharma strategy and the securing of three lucrative contracts can provide confidence in the Company’s growth trajectory. The focus on pharma services post period end may open up new opportunities for partnerships and collaborations, potentially leading to further revenue generation and business expansion.

How will this affect the world?

ANGLE plc’s strategic decision to focus on pharma services and secure contracts with large pharma companies can have a positive impact on the healthcare and biotechnology sectors. By providing innovative circulating tumour cell solutions for research, drug development, and clinical oncology, ANGLE plc is contributing to advancements in cancer treatment and precision medicine. This can ultimately benefit patients worldwide by offering more effective and personalized healthcare solutions.

Conclusion

In conclusion, ANGLE plc’s interim results for the six months ended June 30, 2024, reflect the successful implementation of its large pharma strategy and the Company’s commitment to growth and sustainability. The focus on pharma services and the securing of three lucrative contracts demonstrate ANGLE plc’s potential for future success and positive impact on the healthcare and biotechnology sectors.